EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

APOE Genotyping in Cognitive Disorders: Preliminary Observations from the Greek Population

Athanasia Athanasaki iD, Ioanna Tsantzali iD, Christos Kroupis iD, Aikaterini Theodorou iD, Fotini Boufidou iD, Vasilios C Constantinides iD, John S Tzartos, Socrates J Tzartos, Georgios Velonakis iD, Christina Zompola, Amalia Michalopoulou, Panagiotis G Paraskevas und 6 weitere

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26157410 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Athanasia Athanasaki und 17 weiteren Autor:innen. Beteiligte Einrichtung: 2nd Department of Neurology, School of Medicine, National and Kapodistrian University of Athens, "Attikon" General University Hospital, 12462 Athens,…. Hauptthemen laut MEDLINE: Apolipoproteins E, Alzheimer Disease, Cognitive Dysfunction, Cognition Disorders. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ELPEN Pharmaceutical Co. Inc., NUTRICIA, Roche Diagnostics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer’s disease (AD) is the most common cause of cognitive decline. Among the various susceptibility genes, the gene of apolipoprotein E (APOE) is probably the most important. It may be present in three allelic forms, termed ε2, ε3 and ε4, and the most common genotype is the ε3/ε3. Recently, it has been observed that subjects with the ε4/ε4 genotype may show near-full penetrance of AD biology (pathology and biomarkers), leading to the suggestion that ε4 homozygosity may represent a distinct genetic type of AD. The aim of the present study was to investigate the role of ε4 homozygosity or heterozygosity in the presence or absence of the AD biomarker profile in patients with cognitive disorders in the Greek population. A total of 274 patients were included in the study. They underwent APOE genotyping and cerebrospinal fluid (CSF) biomarker profiling. The presence of ε4 was associated with a lower age of symptom onset and decreased amyloid biomarkers (irrespective to AD or non-AD profiles), and predicted the presence of an AD profile by a positive predictive value approaching 100%. In conclusion, the ε4 allele has a significant effect on the risk and clinical parameters of cognitive impairment and AD in the Greek population, while the ε4/ε4 genotype may be highly indicative of the (co)existence of AD in cognitively impaired patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Apolipoproteins EAlzheimer DiseaseCognitive DysfunctionCognition DisordersHumansGreeceMaleFemaleAgedGenotypeMiddle AgedBiomarkersAllelesGenetic Predisposition to DiseaseAged, 80 and overHeterozygoteApolipoprotein E4

Stichwörter der Autor:innen

Alzheimer’s diseaseamyloid betaapolipoprotein Ecognitive impairmentdementiaphospho-tau proteintau protein

Substanzen

Apolipoproteins EBiomarkersApolipoprotein E4ApoE protein, human

Autor:innen und Institutionen

  • 2nd Department of Neurology, School of Medicine, National and Kapodistrian University of Athens, "Attikon" General University Hospital, 12462 Athens, Greece.
  • Department of Clinical Biochemistry, School of Medicine, National and Kapodistrian University of Athens, "Attikon" General University Hospital, 12462 Athens, Greece.
  • 1st Department of Neurology, School of Medicine, National and Kapodistrian University of Athens, Neurochemistry and Biological Markers Unit, "Eginition" Hospital, 11528 Athens, Greece.
  • Tzartos Neuro Diagnostics, 11523 Athens, Greece.
  • 2nd Department of Radiology, National and Kapodistrian University of Athens, Research Unit of Radiology, "Attikon" General University Hospital, 12462 Athens, Greece.
  • Department of Neurology, University of Tennessee Health Science Center, Memphis, TN 38163, USA.

ORCID-Profile: Athanasia Athanasaki, Ioanna Tsantzali, Christos Kroupis, Aikaterini Theodorou, Fotini Boufidou, Vasilios C Constantinides, Georgios Velonakis, Sotirios Giannopoulos, Paraskevi Moutsatsou, Georgios Tsivgoulis, George P Paraskevas

Förderung

  • ELPEN Pharmaceutical Co. Inc.
  • NUTRICIA
  • Roche Diagnostics

Zitieren

APA

Athanasaki, A., Tsantzali, I., Kroupis, C., Theodorou, A., Boufidou, F., Constantinides, V. C., Tzartos, J. S., Tzartos, S. J., Velonakis, G., Zompola, C., Michalopoulou, A., Paraskevas, P. G., Bonakis, A., Giannopoulos, S., Moutsatsou, P., Tsivgoulis, G., Kapaki, E., & Paraskevas, G. P. (2025). APOE Genotyping in Cognitive Disorders: Preliminary Observations from the Greek Population. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26157410

Vancouver

Athanasaki A, Tsantzali I, Kroupis C, Theodorou A, Boufidou F, Constantinides VC, et al. APOE Genotyping in Cognitive Disorders: Preliminary Observations from the Greek Population. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26157410

BibTeX
@article{Athanasaki2025,
  author = {Athanasaki, Athanasia and Tsantzali, Ioanna and Kroupis, Christos and Theodorou, Aikaterini and Boufidou, Fotini and Constantinides, Vasilios C and Tzartos, John S and Tzartos, Socrates J and Velonakis, Georgios and Zompola, Christina and Michalopoulou, Amalia and Paraskevas, Panagiotis G and Bonakis, Anastasios and Giannopoulos, Sotirios and Moutsatsou, Paraskevi and Tsivgoulis, Georgios and Kapaki, Elisabeth and Paraskevas, George P},
  title = {APOE Genotyping in Cognitive Disorders: Preliminary Observations from the Greek Population},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26157410}
}
Kostenlos starten →